NYSEAMERICAN:IGC IGC Pharma (IGC) Stock Price, News & Analysis $0.45 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.44▼$0.4650-Day Range N/A52-Week Range$0.25▼$0.91Volume89,291 shsAverage Volume164,867 shsMarket Capitalization$33.77 millionP/E RatioN/ADividend YieldN/APrice Target$3.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesOwnershipSEC FilingsShort Interest Get IGC Pharma alerts: Email Address IGC Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside656.0% Upside$3.38 Price TargetShort InterestHealthy1.48% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.26 out of 5 stars 3.5 Analyst's Opinion Consensus RatingIGC Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIGC Pharma has only been the subject of 2 research reports in the past 90 days.Read more about IGC Pharma's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.48% of the outstanding shares of IGC Pharma have been sold short.Short Interest Ratio / Days to CoverIGC Pharma has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IGC Pharma has recently decreased by 9.68%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldIGC Pharma does not currently pay a dividend.Dividend GrowthIGC Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IGC. Previous Next 2.0 News and Social Media Coverage News SentimentIGC Pharma has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for IGC Pharma this week, compared to 1 article on an average week.Search Interest2 people have searched for IGC on MarketBeat in the last 30 days. MarketBeat FollowsOnly 3 people have added IGC Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IGC Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders19.00% of the stock of IGC Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 3.87% of the stock of IGC Pharma is held by institutions.Read more about IGC Pharma's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of IGC Pharma is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IGC Pharma is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIGC Pharma has a P/B Ratio of 4.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."Click here now to watch this exclusive interview About IGC Pharma Stock (NYSEAMERICAN:IGC)IGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development. It also markets Holief, a wellness brand that targets women experiencing premenstrual syndrome and menstrual cramps. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.Read More IGC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IGC Stock News HeadlinesJuly 19, 2024 | msn.comAlliance Global Partners Initiates Coverage of IGC Pharma (IGC) with Buy RecommendationJuly 19, 2024 | finance.yahoo.comIGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price TargetJuly 27, 2024 | Stansberry Research (Ad)Get out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."July 17, 2024 | americanbankingnews.comIGC Pharma (NYSEAMERICAN:IGC) Coverage Initiated at Alliance Global PartnersJune 25, 2024 | businesswire.comIGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's DiseaseJune 18, 2024 | businesswire.comIGC Pharma to Participate in Fireside Chat with Ascendiant Capital MarketsMay 29, 2024 | finance.yahoo.comIGC Pharma enrols two subjects in Alzheimer’s therapy trial at NeurostudiesMay 28, 2024 | businesswire.comIGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1July 27, 2024 | Stansberry Research (Ad)Get out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."May 21, 2024 | businesswire.comIGC Pharma to Attend BIO International Convention 2024May 9, 2024 | stockhouse.com6.7 Million Americans Live With Alzheimer's - IGC Pharma Believes They Deserve Treatment Options Without Black Box WarningsApril 17, 2024 | msn.comCDC investigating reports of counterfeit or mishandled Botox injections in 9 statesApril 16, 2024 | benzinga.comIGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer's-Associated AgitationApril 16, 2024 | stockhouse.comIGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week TwoApril 16, 2024 | finance.yahoo.comIGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week TwoApril 9, 2024 | barrons.comIGC Pharma Inc.April 9, 2024 | businesswire.comIGC Pharma Adds Advisor in Artificial IntelligenceApril 2, 2024 | benzinga.comIGC Pharma Releases Positive Interim Analysis Of Its Ongoing Phase 2 Trial In Alzheimer's ResearchSee More Headlines Receive IGC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IGC Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings6/24/2024Today7/27/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSEAMERICAN:IGC CUSIPN/A CIK1326205 Webwww.igcinc.us Phone(301) 983-0998Fax240-465-0273Employees61Year FoundedN/APrice Target and Rating Average Stock Price Target$3.38 High Stock Price Target$3.50 Low Stock Price Target$3.25 Potential Upside/Downside+656.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,000,000.00 Net Margins-966.54% Pretax Margin-966.54% Return on Equity-119.06% Return on Assets-97.49% Debt Debt-to-Equity Ratio0.02 Current Ratio1.58 Quick Ratio0.93 Sales & Book Value Annual Sales$1.35 million Price / Sales25.01 Cash FlowN/A Price / Cash FlowN/A Book Value$0.11 per share Price / Book4.06Miscellaneous Outstanding Shares75,640,000Free Float61,265,000Market Cap$33.77 million OptionableNot Optionable Beta1.30 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Ram Mukunda (Age 65)President, CEO & Director Comp: $705kMs. Claudia Grimaldi (Age 53)VP, Principal Financial Officer, Chief Compliance Officer & Non-Independent Director Comp: $245kMr. Rohit Goel (Age 30)Senior Director of Accounting & Principal Accounting Officer Key CompetitorsIncannex HealthcareNASDAQ:IXHLCorvus PharmaceuticalsNASDAQ:CRVSInventivaNASDAQ:IVAAmylyx PharmaceuticalsNASDAQ:AMLXImmunicNASDAQ:IMUXView All Competitors IGC Stock Analysis - Frequently Asked Questions How have IGC shares performed this year? IGC Pharma's stock was trading at $0.3446 at the beginning of the year. Since then, IGC stock has increased by 29.5% and is now trading at $0.4464. View the best growth stocks for 2024 here. How were IGC Pharma's earnings last quarter? IGC Pharma, Inc. (NYSEAMERICAN:IGC) announced its quarterly earnings results on Monday, June, 24th. The construction company reported ($0.04) earnings per share (EPS) for the quarter. The construction company earned $0.30 million during the quarter. IGC Pharma had a negative trailing twelve-month return on equity of 119.06% and a negative net margin of 966.54%. How do I buy shares of IGC Pharma? Shares of IGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of IGC Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that IGC Pharma investors own include GW Pharmaceuticals (GWPH), Alibaba Group (BABA), Tilray (TLRY), Cronos Group (CRON), Micron Technology (MU) and NewAge (NBEV). This page (NYSEAMERICAN:IGC) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored4 Steps to Survive the Coming Market CrashCracks threaten us with a widespread collapse unlike anything we've seen in our lifetime. During this prese...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IGC Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IGC Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IGC Stock Alerts